- Hong Kong-listed R&D service provider, Pharmaron Beijing has agreed to acquire Allergan Biologics Limited for $118.7M in cash from AbbVie (NYSE:ABBV).
- Subject to customary closing conditions, the transaction is expected to close in Q2 2021. With over 150 staff, ABL has built its expertise in Cell and Gene Therapy (“CGT”) product development using a suspension system for manufacturing, a statement from Pharmaron said.
- ABL consisting of a flexible cGMP biomanufacturing facility located in Liverpool, UK ‘will further strengthen our CGT services platform and allow us to better serve our partners’ needs in these exciting and emerging therapies,’ commented Boliang Lou CEO of Pharmaron.
- In January, AbbVie-owned Allergan Aesthetics announced a warrant agreement to acquire the privately-held medical device firm Cypris Medical.